Solifenacin Tablets 5mg (Solifenacin Succinate)

Adult dose

The recommended dose for adults (including the elderly) is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This medicine may be taken without regard to meals and should be swallowed whole with water. Dosage adjustment is required for the following patients. 1. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use caution in patients with severe renal impairment (creatinine clearance≤30ml/min) and do not exceed 5mg once daily. 2. Patients with hepatic impairment: No dose adjustment is necessary for patients with mild hepatic impairment. Use caution in patients with moderate hepatic impairment (Child-Pugh class B) and do not exceed 5mg once daily. 3. Patients receiving potent cytochrome P450 3A4 (CYP3A4) inhibitors: For patients receiving ketoconazole or another potent CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This medication should not be used in patients with urinary retention symptoms, severe gastrointestinal conditions, myasthenia gravis, or angle-closure glaucoma. Additionally, individuals allergic to this medication or its components, patients undergoing dialysis, and those with severe liver or kidney impairment should avoid administration. Patients at risk of urinary obstruction or gastrointestinal obstruction, as well as autonomic neuropathy patients, should use this medication cautiously, and dosage adjustment is necessary for those with kidney or liver dysfunction. When taking this medication, symptoms such as dry mouth, constipation, blurred vision, and urinary retention may occur, so these symptoms should be closely monitored. In particular, this medication can cause drowsiness or blurred vision that may require caution while driving or operating machinery. Severe allergic reactions, such as angioedema or anaphylaxis, may also occur; if any unusual symptoms arise, discontinue use immediately and consult a healthcare professional. This medication is metabolized in the liver, so dosage adjustment may be necessary when taken with certain antifungal or antiviral medications, and patients taking such medications must inform their physician. Women who are pregnant or breastfeeding should avoid use as the safety of this medication has not been established. This medication should not be administered to children, as the safety and efficacy have not been validated. In cases of overdose, inducing vomiting should be avoided, and appropriate emergency treatment such as gastric lavage or administration of activated charcoal should be received if necessary. Patients with heart disease or at risk of QT prolongation should be particularly cautious and should consult a healthcare professional prior to taking this medication.

• Dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• fecal impaction
• colonic obstruction
• intestinal obstruction
• angioedema
• nausea

This medication should be stored in a tightly sealed container to prevent exposure to air or humidity. Additionally, it is best to store it at room temperature between 1 degree and 30 degrees Celsius.

Appearance

Bright yellow circular film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle